Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease

Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease

Sponsors

Lead Sponsor: Huntington Medical Research Institutes

Collaborator: GlaxoSmithKline

Source Huntington Medical Research Institutes
Brief Summary

Lovaza is the only fish oil supplement approved by the FDA. It is available by prescription for the treatment of hypertriglyceridemia (> 500 mg/dl). The primary mechanism appears to be a reduction in hepatic production of triglycerides. Also decreases the hepatic production of very low density lipoprotein (VLDL). There also may be antioxidant properties as well. The thought behind using Lovaza as a treatment for non-alcoholic fatty liver disease (NAFLD) is two fold. It would help in the decrease production of triglycerides by the liver and have antioxidant properties decreasing the production of free radicals in the liver. In doing so, steatohepatitis, fibrosis, and perhaps cirrhosis and liver cancer would be prevented.

Overall Status Unknown status
Start Date September 2009
Completion Date September 2012
Primary Completion Date September 2012
Phase Phase 4
Study Type Interventional
Primary Outcome
Measure Time Frame
To determine if Lovaza improves fibrosis and the NASH activity index. 48 weeks
Secondary Outcome
Measure Time Frame
To determine if Lovaza improves AST/ALT level and improves steatosis on biopsy. 48 weeks
Enrollment 40
Condition
Intervention

Intervention Type: Drug

Intervention Name: Lovaza

Description: Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.

Arm Group Label: Lovaza

Intervention Type: Drug

Intervention Name: placebo control

Description: Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.

Arm Group Label: Placebo

Eligibility

Criteria:

Inclusion Criteria:

- Over the age of 18

- Abnormal liver enzymes >40 IU/L. Definition of normal is ALT 19 for a woman and 30 for a man.

- Patients must meet ATP III criteria for metabolic syndrome: Central obesity as measured by waist circumference. Men - greater than or equal to 40 inches. Women - greater than or equal to 35 inches.

- Blood HDL cholesterol. Men - less than 40 mg/dL. Women - less than 50 mg /dL.

- Blood pressure greater than or equal to 130/85.

- Fasting glucose greater than or equal to 100 mg/dL but less than 126mg/dL on 2 separate occasions.

- Fasting blood triglycerides greater than or equal to 150 mg/dL.

- Hepatitis B and C negative

- Autoimmune Hepatitis, Wilson's Disease, Hemochromatosis negative, etc.

- NASH or NAFLD on biopsy of any degree:

Exclusion Criteria:

- Below the age of 18.

- Other Causes of Liver inflammation.

- Daily alcohol consumption in excess of 20 grams / day for men and 10 grams / day for women. If participant unable to quantify his/her alcohol intake, they should be excluded.

- Taking a prescribed medication know to cause fatty liver disease 6 months prior to enrollment. Also, subjects with secondary causes of fatty liver disease (ie. Gastric bypass) should be excluded from the study.

- Cirrhosis.

- Subjects on oral insulin-sensitizing agents and other drugs currently being used in the treatment of NAFLD. Such agents include fibrates, Vitamin E, S-adenosyl-methionine, betaine, N-acetylcysteine, and milk thistle extracts.

- Diabetes (fasting sugar above 126mg/dl).

- Pregnancy or lactation. Women of child bearing potential must have a negative serum pregnancy test at screening, a negative urine pregnancy test prior to treatment and be practicing an acceptable form of barrier contraception for the duration of the study.

- Any serious or chronic disease that in the opinion of the Principal Investigator (PI), may affect the assessment of safety or efficacy parameters. This includes but is not limited to, patients with malignancy, other than Basal Cell Carcinomas.

- Patients who, in the opinion of the site PI, are not suitable candidates for enrollment or would not comply with the requirements of the study.

- Patients who have had a liver transplant.

- Any allergy to fish.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Overall Contact

Last Name: Roberta A Fitzgerald, RN

Phone: 626.397.5825

Email: [email protected]

Location
Facility: Status: Contact: Investigator: HMRI - Liver Center Roberta A Fitzgerald, RN 626-397-5825 [email protected] Edward A Mena, MD Principal Investigator Myron J Tong, PhD, MD. Sub-Investigator
Location Countries

United States

Verification Date

June 2010

Responsible Party

Name Title: Edward A. Mena, MD

Organization: Huntington Medical Research Institutes

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: Lovaza

Type: Active Comparator

Description: Single blind, active treatment arm Lovaza, is the only fish oil supplement approved by the FDA. The Lovaza treatment group will take 4g of Lovaza daily for a minimum of 48 weeks.

Label: Placebo

Type: Placebo Comparator

Description: Single blind, Placebo arm study drug will contain 994.0 mg of corn oil and 6mg of alpha tocopherol as an excipient in a soft gelatin capsule shell. Subjects will take 4g daily for a minimum of 48 weeks.

Study Design Info

Allocation: Randomized

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: Single (Participant)

Source: ClinicalTrials.gov